Blockade of IDO1 activity decreased tumor proliferation in a T-lymphocyte-mediated manner and enhanced the efficacy of chemotherapy, radiotherapy, targeted therapy, and immunotherapy [15–19]. This evidence concerns the gene IDO1 and neoplasm.